Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Xsira Pharmaceuticals

Request full access

Biotechnology company that uses proprietary technology for the discovery and development of drugs

Morrisville, United StatesFounded 1999Biotech & Life Sciences

About Xsira Pharmaceuticals

Originally founded as Norak Biosciences, Inc. in 1999, the company rebranded to Xsira Pharmaceuticals, Inc. in 2005. As a biopharmaceutical entity, its primary focus was on the discovery and development of drugs centered around G protein-coupled receptors (GPCRs). The company's core asset was its proprietary Transfluor technology, a cell-based screening method licensed from Duke University. This platform was designed to measure GPCR activity, a key process in regulating the body's response to drugs for conditions like asthma, heart problems, and pain.

The Transfluor technology offered a universal, high-content screening assay applicable to both known and orphan GPCRs, which are receptors whose natural ligands are yet to be identified. By identifying small molecule compounds that modulate these receptors, the company aimed to develop pharmaceutical candidates for significant medical needs and large markets. The technology was particularly focused on researching compounds with better desensitization profiles to address drug tolerance and resistance. In early 2005, a significant strategic shift occurred when Xsira sold its Transfluor drug technology to Molecular Devices. Following this sale, the company licensed the rights to adenosine, a clinical-stage analgesic for post-surgical pain, indicating a move away from early-stage discovery towards later-stage drug development. Shortly after these strategic changes and the rebranding in 2005, the company significantly downsized its workforce, retaining only a few management personnel.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
22.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Feb 2002 $13M $52M Intersouth Partners · Aurora Funds · Noro-Moseley Partners · Koch Enterprises ↗
SPINOUT✓Other financing Jan 1999 $0 — Duke University —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Xsira Pharmaceuticals website traffic

Latest recorded traffic for Xsira Pharmaceuticals is 1.1K monthly website visits, up 64.2% over the last three months.

Latest monthly visits1.1K 3-month web change+64.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Xsira Pharmaceuticals in the Morrisville ecosystem

Live from Dealroom

The Xsira Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Intersouth Partners
  • Aurora Funds
  • Noro-Moseley Partners
  • Koch Enterprises
  • Mitsui Global Investment
  • Alexandria Venture Investments

Other known investors1 additional known investor

  • Duke University
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Morrisville HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Xsira Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Xsira Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.